ARCHIVES

Texas Oncology Designated Aranesp As Preferred Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 46 | December 13, 2002

Download PDF Visit The Full Archive

Related Articles

NIH “Just In Time” Procedure Expanded For Two Awards

April 12, 1996

AACR Statement on Precancers Plays Key Role in NCI Agenda

May 30, 2003

FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.

March 23, 2001

IDMC Halts Mekinist-Tafinlar Trial Early Due to OS Benefit; Recommends Crossover

July 25, 2014

National Coalition Dinner Honors Cancer Program Founders, Advocates, And Cancer Survivors

March 6, 1992

Turnover In Immunology Contracts To Free Up Substantial Sums, Possible New RFPs Listed

October 8, 1976